Drug Overview
Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA. In preclinical studies, Xtandi was shown to provide a more complete suppression of the AR than Casodex (bicalutamide; AstraZeneca).
Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA. In preclinical studies, Xtandi was shown to provide a more complete suppression of the AR than Casodex (bicalutamide; AstraZeneca).
Table of Contents
Product ProfilesXtandi: Prostate cancer
List of Figures
Figure 1: Xtandi for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Xtandi for prostate cancer
Figure 3: Drug assessment summary of Xtandi for prostate cancer
Figure 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Xtandi drug profile
Table 2: Xtandi Phase III data in prostate cancer
Table 3: Xtandi Phase III trials in prostate cancer
Table 4: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
